Swedbank AB Sells 14,006 Shares of Abbott Laboratories $ABT

Key Points

• Swedbank AB reduced its holdings in Abbott Laboratories by 0.9%, selling 14,006 shares to hold approximately 1.6 million shares, valued at $219.56 million.
• Abbott Laboratories received several upgrades from analysts, with Jefferies Financial Group and William Blair both assigning a "buy" or "strong buy" rating and raising price targets to between $141 and $145.
• In Q2 2025, Abbott Laboratories reported earnings per share of $1.26 and forecasted FY 2025 EPS guidance between 5.100 and 5.200.

Swedbank AB reduced its position in Abbott Laboratories (NYSE:ABT - Free Report) by 0.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,614,322 shares of the healthcare product maker's stock after selling 14,006 shares during the quarter. Swedbank AB owned 0.09% of Abbott Laboratories worth $219,564,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. Hughes Financial Services LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter worth $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the first quarter worth about $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories during the first quarter worth approximately $30,000. JCIC Asset Management Inc. purchased a new position in shares of Abbott Laboratories during the first quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories during the first quarter valued at approximately $33,000. Institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ABT shares. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Royal Bank Of Canada increased their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and increased their price objective for the company from $143.00 to $145.00 in a report on Friday, July 18th. BTIG Research lowered their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, July 18th. Finally, Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $145.22.

Abbott Laboratories Trading Up 0.6%

Shares of Abbott Laboratories stock traded up $0.78 during trading hours on Monday, hitting $136.82. The company's stock had a trading volume of 4,837,007 shares, compared to its average volume of 5,199,671. The business has a fifty day moving average of $130.56 and a 200 day moving average of $131.11. The company has a market capitalization of $238.13 billion, a PE ratio of 17.15, a P/E/G ratio of 2.58 and a beta of 0.69. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. The company had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.7%. Abbott Laboratories's payout ratio is 29.57%.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.